

PRECEPTORSHIP PROGRAMME

Ovarian Cancer

**ESMO
PRECEPTORSHIP**

**LISBON PORTUGAL
23-24 SEPTEMBER 2022**

Multidisciplinary management, standards of care, therapeutic targets and future perspectives.

Chairs:

Susana Banerjee, United Kingdom
Isabelle Ray-Coquard, France

ESMO PRECEPTORSHIP PROGRAMME OVARIAN CANCER

Multidisciplinary management, standards of care
and future perspectives

23-24 September 2022
Lisbon, Portugal

CO-CHAIRS: Susana Banerjee, United Kingdom
Isabelle Ray-Coquard, France

SPEAKERS: Mojgan Devouassoux-Shisheboran, France
Christina Fotopoulou, United Kingdom
Antonio González-Martín, Spain
Intidhar Labidi-Galy, Switzerland
Alexandra Leary, France
Sven Mahner, Germany
Delia Mezzanzanica, Italy
Philippe Morice, France
Xavier Paoletti, France
Toon Van Gorp, Belgium

LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of early and late stage ovarian cancer
- To understand the importance of biology and pathology of common and rare ovarian tumours
- To understand the options for treatment of recurrent disease and how treatment decisions are made
- To understand the novel therapeutic agents being developed to treat ovarian cancer and how knowledge of genomics and molecular pathways guides drug development
- To learn about the management of patients with symptoms of the disease and the side effects of treatment

ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 23 September 2022

09:00-09:10 10'	Welcome and introduction	Susana Banerjee, UK Isabelle Ray-Coquard, FR
09:10-10:25 75'	SESSION 1 Early stage	Chairs: Alexandra Leary, FR Isabelle Ray-Coquard, FR
20'	Pathology and staging of early epithelial ovarian cancer and rare ovarian tumours	Mojgan Devouassoux-Shisheboran, FR
20'	Surgery for early ovarian cancer: Staging and conservative surgery	Christina Fotopoulou, UK
20'	Clinical management of early ovarian cancer	Isabelle Ray-Coquard, FR
15'	Q&A	All
10:25-11:00	Coffee break	
11:00-13:35 155'	SESSION 2 Advanced disease at diagnosis	Chairs: Antonio González-Martín, ES Sven Mahner, DE
20'	Biology of high-grade tubo-epithelial cancers, including biomarkers in practice	Intidhar Labidi-Galy, CH
20'	Surgery for newly diagnosed advanced ovarian cancer	Sven Mahner, DE
20'	First-line chemotherapy treatment	Antonio González-Martín, ES
20'	Maintenance therapy for newly diagnosed advanced ovarian cancer	Isabelle Ray-Coquard, FR
3x20'	3 x Participant clinical case discussion	All
15'	Q&A	All
13:35-14:35	Lunch	
14:35-15:50 75'	SESSION 3 Rare cancers	Chairs: Susana Banerjee, UK Isabelle Ray-Coquard, FR
20'	Genomic profiling for rare ovarian cancer	Alexandra Leary, FR
20'	Rare non-epithelial tumours: Treatment	Isabelle Ray-Coquard, FR
20'	Rare epithelial tumours: Low-grade serous, clear cell and carcinosarcoma treatment	Susana Banerjee, UK
15'	Q&A	All
15:50-18:50 150'	SESSION 4 Recurrent disease and complex cases	Chairs: Christina Fotopoulou, UK Antonio González-Martín, ES
20'	Overview of systemic treatment for recurrent ovarian cancer	Toon Van Gorp, BE
20'	The role of surgery in recurrent ovarian cancer	Christina Fotopoulou, UK

16:30-17:00	Coffee Break	
3x20'	3 x Participant clinical case discussion	All
20'	Management of ovarian cancer in older patients	Antonio González-Martín, ES
20'	Fertility	Philippe Morice, FR
10'	Q&A	All
20:30	Dinner	

Saturday, 24 September 2022

09:30-11:10 100'	SESSION 5 Biology and methodologies - All we need to develop future strategies	Chairs: Susana Banerjee, UK Toon Van Gorp, BE
25'	Biology and clinical implications of drug resistance	Intidhar Labidi-Galy, CH
25'	A clinician's guide to cancer genomics	Delia Mezzanzanica, IT
25'	Clinical trial design, meta-analysis, PRO and QoL	Xavier Paoletti, FR
25'	Q&A	All
11:10-11:30	Coffee break	
11:30-12:45 75'	SESSION 6 Future treatments	Chairs: Isabelle Ray-Coquard, FR Toon Van Gorp, BE
25'	Immunotherapy: Current evidence and future prospects	Toon Van Gorp, BE
25'	Novel treatment pathways and combinations: Horizon scanning	Susana Banerjee, UK
25'	Q&A	All
12:45-12:55 10'	Conclusion and farewell	Susana Banerjee, UK Isabelle Ray-Coquard, FR
12:55-13:55	Lunch	

Note: Each 20 min slot for clinical case discussion includes 7' to 10' case presentation and 10' to 13' Q&A / panel discussion